Hadassah1000, H1K

H1K: Oral Anti-Obesity Drugs

Obesity is a chronic, recurrent, complex disease characterized by excess body weight. Obesity is influenced by a combination of factors including genetics, hormones, behavior, and the environment. Being obese increases the risk of several disorders such as diabetes, high blood pressure, heart disease, and certain cancers, and can lead to premature death.

Global obesity treatment sales are expected to reach $6.68 billion (approximately KRW 9 trillion) in 2023, up 145.6% from $2.72 billion in 2022. The obesity treatment market is expected to grow rapidly at an annual average of 30.2% from 2023 (Mirae Asset Securities Research Center).

The proportion of drug therapy in obesity treatment is less than 3%, so there is still a high unmet need, and the emergence of new obesity drugs in the GLP-1 incretin hormone series, which are effective and convenient for patients with a weight loss rate of 15% or more, is changing the perception of patients, doctors, and insurance companies, and as innovation in new drug development continues, the rapid growth of the obesity treatment market is expected to continue in the mid- to long-term.

Currently, effective oral third-generation obesity drugs, new mechanisms, and combination therapies are being actively developed, and just as the GLP-1 diabetes new drug market expanded to obesity, it is expected to expand from obesity to cardiovascular disease and metabolic disease in the future.

Hadassah1000 (H1K) is a synthetic peptide substance that has the effect of reducing weight and liver fat. This substance partially stimulates the IGF-1 receptor in our body, thereby increasing blood sugar control and fat burning ability, thereby reducing weight. It also blocks part of CD28 to reduce inflammation, preventing fat from accumulating in the liver. It is currently being developed as an oral medication for obese patients, and its effectiveness and mode of action are being studied.